Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently.

Methods

In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety.

Results

A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups.

Conclusions

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728. opens in new tab.)

Click here to read the full journal article.

Source: New England Journal of Medicine

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

NEW REPORT – Policy Priorities for Super-Ageing Japan: Health Innovation and Economic Growth in the COVID-19 Pandemic Era

New York and Tokyo (February 24, 2021) – Today, the Global Coalition on Aging (GCOA) and the Health and Global Policy Institute (HGPI) announced a report sharing key takeaways from their roundtable on healthy aging, innovation, and the silver economy. The October 2020 virtual roundtable convened experts from across the health, business, aging, and elder homecare sectors in a policy discussion to call on governments to recognize health spending as a critical investment for countries like Japan, who are leading the global megatrend of aging and placing innovation at the center of this investment.

Global Coalition on Aging Partners with the World Summit on the Information Society (WSIS) Forum 2021

New York, NEW YORK (February 23, 2021) – The World Summit on the Information Society (WSIS) Forum 2021 and the Global Coalition on Aging (GCOA) announce their collaboration on the first-ever WSIS Forum Healthy Ageing Innovation Prize to be awarded  at the WSIS Forum 2021.  The prize will be awarded to the most innovative technology that enables healthier and more active ageing and will be presented in parallel with the WSIS Forum 2021 Special Track on ICTs and Older Persons, which is designed, organized and supported by GCOA.

NEW REPORT – The Threat of AMR to Japan’s Super-Aging Society: Implications on Health Care, Public Policy, and Economic Well-Being

New York and Tokyo (February 21, 2021) – Today, the Global Coalition on Aging (GCOA) and the Health and Global Policy Institute (HGPI) announced a report sharing key policy-focused takeaways from their roundtable on antimicrobial resistance (AMR) in super-aging Japan. On October 7, 2020, the roundtable convened experts from across the business, government, academic, aging, and non-profit sectors in a policy discussion that recognized the multifaceted risks of AMR in aging societies around the world, including super-aging Japan.

WSIS Forum 2021 and the Global Coalition on Aging Partner on Hackathon to Inspire Cutting-Edge ICT Innovation for Older Persons

New York, NEW YORK (February 18, 2021) – The World Summit on the Information Society (WSIS) and the Global Coalition on Aging (GCOA) today announce their partnership on the Ageing Better Through ICTs hackathon, a first-of-its-kind global hackathon focused on innovation for the Silver Economy. The hackathon, conducted virtually, will draw participants from around the world and of all ages to generate ideas for information and communication technologies (ICTs) to improve the lives of older persons.

​​​​Global Coalition on Aging and Pfizer Medical Grants Partner to Tackle Vaccine Hesitancy in Super-Aging Japan

New York, NEW YORK (February 17, 2021) – The Global Coalition on Aging and Pfizer Global Medical Grants announced today the launch of the first of its grant projects under the Japan-focused VALUE Initiative (Vaccines for All: Longevity Unleashed for Everyone), which has provided up to $1 million USD in grant awards. Grant recipients include Keio University, the Health and Global Policy Institute (HGPI), and the International Longevity Centre-UK.

Cross-Sector Panel of Experts Offers Trusted Guidance and Answers New Yorkers’ Questions on the Importance of Older Adult New Yorkers Getting Vaccinated Against Covid-19

New York, NEW YORK (January 21, 2021) – The New York City Department for the Aging, the Age-friendly NYC Commission, and the Global Coalition on Aging (GCOA), the world's leading business voice on aging, collaborated yesterday on a webinar to help build trust and acceptance of the Covid-19 vaccines for New York’s older adults.